Mozafari, P. et al. 2026. Balancing Long-Term Efficacy and Immunological Safety: Serious Infection Risk during Extended Ocrelizumab Therapy in Multiple Sclerosis. Junior Researchers. 4, 2 (Jul. 2026), 57–69. DOI:https://doi.org/10.52340/jr.2026.04.02.04.